At its recent analyst day, InterMune Inc. updated investors on plans for the confirmatory trial required to obtain U.S. approval for its idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone), which the FDA slapped with a complete response letter last year.

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry.

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry.